Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.53 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353930 | 0.96 | MAOB (0.59) | MAOBNR1H3APPMAOAHCRTR2 | |
| SCHEMBL11266108 | 0.89 | MAOB (0.56) | MAOBNR1H3APPMAOAHCRTR2 | |
| SCHEMBL5347615 | 0.89 | MAOB (0.52) | MAOBNR1H3HCRTR2 | |
| SCHEMBL5347623 | 0.89 | MAOB (0.52) | MAOBNR1H3HCRTR2 | |
| SCHEMBL5359397 | 0.89 | MAOB (0.52) | MAOBNR1H3HCRTR2 | |
| SCHEMBL11360157 | 0.83 | MAOB (0.43) | MAOBNR1H3APPMAOAKDM4E | |
| SCHEMBL5351629 | 0.82 | MAOB (0.48) | MAOBNR1H3HCRTR2 | |
| SCHEMBL5366696 | 0.82 | MAOB (0.49) | MAOBNR1H3HCRTR2 | |
| SCHEMBL10713816 | 0.78 | MAOB (0.55) | MAOBNR1H3APPMAOAHCRTR2 | |
| SCHEMBL5353150 | 0.78 | KDM4E (0.44) | NR1H3APPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | claimed |
| JP-2006514925-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1497270-A4 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | claimed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| EP-0005848-B1 | N-ALKYLATED AMINOALCOHOLS AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | claimed |
| US-7247748-B2 | Amide compounds and methods of using the same | SMITHKLINE CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1497270-A4 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050107444-A1 | Amide compounds and methods of using the same | GLAXOSMITHKLINE LLC | 2005-05-19 | — | — | US | disclosed |
| EP-1497270-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SmithKline Beecham Corporation (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004043939-A1 | AMIDE COMPOUNDS AND METHODS OF USING THE SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-4460580-A | N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0005848-B1 | N-ALKYLATED AMINOALCOHOLS AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | disclosed |
| EP-0005848-A1 | N-Alkylated aminoalcohols and their salts, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107444-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | MAOB 3302/4885NR1H3 2/4885APP 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.